Tamoxifen inhibits cancer cell interactions with platelets, which decreases platelet activation and the release of TGF-β1, platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), interleukin 6 (IL-6) and insulin like growth factor (IGF-1) from platelets into the TME [1,46,47,54]. The gene discussed is IL6; the disease is cancer.